BR112015000313A2 - piperazino[1,2-a]indol-1-onas e [1,4]diazepino[1,2-a]indol-1-ona - Google Patents

piperazino[1,2-a]indol-1-onas e [1,4]diazepino[1,2-a]indol-1-ona

Info

Publication number
BR112015000313A2
BR112015000313A2 BR112015000313A BR112015000313A BR112015000313A2 BR 112015000313 A2 BR112015000313 A2 BR 112015000313A2 BR 112015000313 A BR112015000313 A BR 112015000313A BR 112015000313 A BR112015000313 A BR 112015000313A BR 112015000313 A2 BR112015000313 A2 BR 112015000313A2
Authority
BR
Brazil
Prior art keywords
lower alkyl
halogen
substituted
indol
disease
Prior art date
Application number
BR112015000313A
Other languages
English (en)
Inventor
Wichmann Juergen
Jagasia Ravi
Jakob-Roetne Roland
Maria Ceccarelli Simona
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112015000313A2 publication Critical patent/BR112015000313A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)

Abstract

resumo patente de invenção: "piperazino[1,2-a]indol-1-onas e [1,4]diazepino[1,2-a]indol-1-ona". a presente invenção refere-se aos compostos de fórmula geral (i), em que r1 é hidrogênio, halogênio, alquila inferior, alcóxi inferior, alcóxi inferior substituído por halogênio ou ciano; r2 é hidrogênio, alquila inferior ou alquila inferior substituída por halogênio; r3 é fenila, benzo[1,3]dioxolila, 2,3-di-hidro-benzofuran-5-ila ou uma heteroarila de 5 e 6 membros, em que a fenila e os grupos heteroarila com 5 e 6 membros podem ser substituídos por um ou mais substituintes, selecionados de ciano, nitro, amino e di-alquilamino inferior, sulfonil de alquila inferior, alcóxi inferior, alcóxi inferior substituído por halogênio, halogênio, alquila inferior, alquila inferior substituída por halogênio ou alquila inferior substituída por hidroxila; x é -ch(alquila inferior)-, -ch2-, -ch2ch2- ou -ch(alquila inferior)ch2-; r é hidrogênio ou alquila inferior; n é 1 ou 2; ou a um sal de adição de ácido farmaceuticamente aceitável, a uma mistura racêmica ou a seu correspondente enantiômero e/ou isômeros ópticos dos mesmos. os compostos podem ser empregados para o tratamento de esquizofrenia, transtorno da personalidade obsessivo-compulsiva, depressão maior, transtornos bipolares, transtornos de ansiedade, envelhecimento normal, epilepsia, degeneração da retina, lesão cerebral traumática, lesão da medula espinhal, transtorno do estresse pós-traumático, transtorno do pânico, doença de parkinson, demência, doença de alzheimer, comprometimento cognitivo brando, disfunção cognitiva induzida por quimioterapia, síndrome de down, transtornos de espectro autista, perda de audição, tinido, ataxia espinocerebelar, esclerose amiotrófica lateral, esclerose múltipla, doença de huntington, acidente vascular cerebral, terapia de radiação, estresse crônico, abuso de fármacos neuroativos, tais como álcool, opiáceos, metanfetamina, fenciclidina e cocaína.
BR112015000313A 2012-08-06 2013-08-05 piperazino[1,2-a]indol-1-onas e [1,4]diazepino[1,2-a]indol-1-ona BR112015000313A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12179381 2012-08-06
PCT/EP2013/066344 WO2014023674A1 (en) 2012-08-06 2013-08-05 Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one

Publications (1)

Publication Number Publication Date
BR112015000313A2 true BR112015000313A2 (pt) 2017-06-27

Family

ID=48918402

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015000313A BR112015000313A2 (pt) 2012-08-06 2013-08-05 piperazino[1,2-a]indol-1-onas e [1,4]diazepino[1,2-a]indol-1-ona

Country Status (25)

Country Link
US (1) US9284321B2 (pt)
EP (1) EP2880036B1 (pt)
JP (1) JP5974177B2 (pt)
KR (1) KR101716062B1 (pt)
CN (1) CN104540829B (pt)
AR (1) AR092041A1 (pt)
AU (1) AU2013301577B2 (pt)
BR (1) BR112015000313A2 (pt)
CA (1) CA2880682A1 (pt)
CL (1) CL2015000143A1 (pt)
CO (1) CO7141435A2 (pt)
CR (1) CR20140545A (pt)
EA (1) EA025884B1 (pt)
HK (1) HK1206355A1 (pt)
IL (1) IL236808B (pt)
MA (1) MA37791B1 (pt)
MX (1) MX362184B (pt)
MY (1) MY185216A (pt)
NZ (1) NZ703192A (pt)
PE (1) PE20150341A1 (pt)
PH (1) PH12015500059A1 (pt)
SG (1) SG11201408529VA (pt)
TW (1) TWI506027B (pt)
UA (1) UA113013C2 (pt)
WO (1) WO2014023674A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4089397A1 (en) * 2013-02-18 2022-11-16 Labrador Diagnostics LLC System for optically analyzing a sample
BR112015020179A2 (pt) * 2013-04-02 2017-07-18 Hoffmann La Roche piperazino[1,2-a]indol-1-onas e [1,4]diazepino[1,2-a]indol-1-onas
KR101716099B1 (ko) * 2013-09-12 2017-03-13 에프. 호프만-라 로슈 아게 인돌-카복스아마이드 유도체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3702321A (en) * 1968-02-13 1972-11-07 Sumitomo Chemical Co Process for preparing benzodiazepine derivatives
GB0106177D0 (en) * 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
AU2006324089A1 (en) * 2005-12-09 2007-06-14 F. Hoffmann-La Roche Ag Tricyclic amide derivatives useful for treating obesity
WO2008046072A2 (en) 2006-10-13 2008-04-17 The Board Of Regents Of The University Of Texas System Chemical inducers of neurogenesis
EP2084131A1 (en) * 2006-11-09 2009-08-05 F. Hoffmann-Roche AG Indole and benzofuran 2-carboxamide derivatives
JP6126528B2 (ja) 2010-07-07 2017-05-10 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムＴｈｅ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｅｘａｓ Ｓｙｓｔｅｍ 神経新生促進化合物
BR112015020179A2 (pt) * 2013-04-02 2017-07-18 Hoffmann La Roche piperazino[1,2-a]indol-1-onas e [1,4]diazepino[1,2-a]indol-1-onas

Also Published As

Publication number Publication date
MA37791A1 (fr) 2016-05-31
EA025884B1 (ru) 2017-02-28
CN104540829A (zh) 2015-04-22
IL236808B (en) 2018-05-31
CO7141435A2 (es) 2014-12-12
US9284321B2 (en) 2016-03-15
AR092041A1 (es) 2015-03-18
TWI506027B (zh) 2015-11-01
EA201590125A1 (ru) 2015-05-29
MX2015001318A (es) 2015-04-17
CL2015000143A1 (es) 2015-06-19
JP2015524456A (ja) 2015-08-24
MA37791B1 (fr) 2016-12-30
JP5974177B2 (ja) 2016-08-23
AU2013301577A1 (en) 2014-12-18
NZ703192A (en) 2016-04-29
AU2013301577B2 (en) 2017-03-30
PH12015500059B1 (en) 2015-03-02
WO2014023674A1 (en) 2014-02-13
US20150246922A1 (en) 2015-09-03
EP2880036A1 (en) 2015-06-10
EP2880036B1 (en) 2017-03-08
HK1206355A1 (en) 2016-01-08
CR20140545A (es) 2015-01-12
PH12015500059A1 (en) 2015-03-02
PE20150341A1 (es) 2015-02-28
KR101716062B1 (ko) 2017-03-13
KR20150027832A (ko) 2015-03-12
UA113013C2 (uk) 2016-11-25
SG11201408529VA (en) 2015-01-29
CN104540829B (zh) 2017-04-26
MX362184B (es) 2019-01-08
TW201410679A (zh) 2014-03-16
MY185216A (en) 2021-04-30
CA2880682A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
BR112015004942A2 (pt) benzimidazóis como agentes ativos do snc
MX2016008842A (es) Derivados de n-fenil-lactama capaces de estimular la neurogenesis y su uso en el tratamiento de trastornos neurologicos.
AR096640A1 (es) Derivados de indolin-2-ona o pirrolo-piridin / pirimidin-2-ona
BR112015027362A2 (pt) derivados de isoquinolina estimulantes de neurogênese
MX2016000895A (es) Derivados de 1,7-naftiridina.
AR093576A1 (es) Derivados heterociclicos sustituidos
MX2012010657A (es) Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico.
BR112017022568A2 (pt) compostos e seus usos como inibidores de bace1
MX2015006364A (es) 1,6-naftiridinas sustituidas.
EP2562176A4 (en) MEDICINAL AGENT AND DRINK / FOOD TO PREVENT BRAIN DYSFUNCTION AND IMPROVE SYMPTOMS
BR112015000313A2 (pt) piperazino[1,2-a]indol-1-onas e [1,4]diazepino[1,2-a]indol-1-ona
AR079103A1 (es) Compuesto de sal de mesilato de (s) -2-(4-(3-fluoro-benciloxi)-bencilamino)-propionamida, forma polimorfica (nf6) , composicion farmaceutica, uso del mismo para la preparacion de un medicamento y su procesos de preparacion
PH12016500605A1 (en) Pyrido[4,3-b]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders
BR112015008200A2 (pt) derivados de imidazopiridina
BR112015020179A2 (pt) piperazino[1,2-a]indol-1-onas e [1,4]diazepino[1,2-a]indol-1-onas
BR112016024149A2 (pt) derivados de indolin-2-ona e 1,3-di-hidro-pirrol[3,2-c]piridin-2-ona
MX2016001528A (es) Derivados de indol-carboxamida.
MX2015000629A (es) Moduladores de benzisoxasol de neurogenesis.
TH167754A (th) ไพเพอราซิโน[1,2-a]อินดอล-1-โอนและ[1,4]ไดอะซีพิโน[1,2-a]อินดอล-1-โอน
TH165816A (th) ไพริโด[4,3-b]ไพราซีน-2-คาร์บอกซาไมด์ ในรูปสารก่อกำเนิดประสาทสำหรับ การรักษาความผิดปกติที่มีภาวะเสื่อมของระบบประสาท
TH165816B (th) ไพริโด[4,3-b]ไพราซีน-2-คาร์บอกซาไมด์ ในรูปสารก่อกำเนิดประสาทสำหรับ การรักษาความผิดปกติที่มีภาวะเสื่อมของระบบประสาท
RU2009113029A (ru) Комбинации, содержащие производное 4-ациламинопиридина

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements